IOL Chemicals and Pharmaceuticals Q2FY23 net profit drops to Rs 15.6 Cr
The company registered with REACH Certificate for Ethyl Acetate with a tonnage band of more than 1000 TPA
The company registered with REACH Certificate for Ethyl Acetate with a tonnage band of more than 1000 TPA
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
The dividend cheque of Rs. 9.93 crore for the Ministry of Ayush was handed over to Sonowal
The Group will continue to make proactive investments of its management resources in the life science business
Doxycycline Capsules (RLD Oracea) had estimated annual sales of US $215 million in the US
The company has successfully developed Methyl salicylate using Flow Chemistry and successfully erected a Flow reactor at Jhagadia plant and expects to start production from Q3 FY23
Revenue from operations for the half year was Rs. 178.5 crore, declined by 23% whereas net profit for the half year was Rs. 16.9 crore, declined by 70%
Pantoprazole Sodium Sesquihydrate are proton pump inhibitors used in drugs to suppress the gastric acid secretion
Drospirenone Tablets (RLD Slynd) had estimated annual sales of US $141 million in the US
Subscribe To Our Newsletter & Stay Updated